Autolus Therapeutics plc has scheduled presentations at two prominent investor conferences in March 2026, providing opportunities to discuss recent corporate developments and commercial progress. The company will participate in the TD Cowen Health Care Conference on March 3 and the Jefferies Biotech on the Beach Summit on March 10, where management is expected to address investors and industry stakeholders.
The conference participation coincides with the release of preliminary unaudited financial results for the fourth quarter and full year 2025, which include net product revenue figures from AUCATZYL® sales. The timing allows the company to present its commercial performance alongside updates on pipeline advancement initiatives and strategic priorities for the upcoming year.
These investor forums provide Autolus with a platform to communicate its 2026 outlook and therapeutic development progress to the broader investment community during a period of continued focus on CAR-T cell therapy innovations and market expansion.